UBS believes that ABBISKO-B's stock has been oversold, as its valuation is low compared to its biotech peers. The firm maintains a positive outlook on the company's product pipeline and has reiterated a Buy rating, although it has lowered the target price from HKD22.9 to HKD17.5.
